NCT06421038

Brief Summary

Recurrent aphthous stomatitis (RAS) is considered the most common oral mucosal lesion, present first in childhood or adolescence. Aphthous ulcers affect up to 25% of the general population, and 3-month recurrence rates are as high as 50%, it is more common in female, also it increases by increasing age and minor aphthous ulcers are 80% of suffered patient. Due to the antimicrobial, anti-inflammatory, antifungal, and analgesic effects of Thyme honey, and the lack of evidence in the considered population, the present study aimed to assess the effect of honey on the pain relief in patients with minor RAU as a primary objective and to assess the healing effect of natural thyme honey on minor RAU, and the Oral Health Impact Profile (OHIP-14) as a secondary objectives.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2024

Completed
3 days until next milestone

Study Start

First participant enrolled

May 10, 2024

Completed
5 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 20, 2024

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2024

Completed
Last Updated

May 20, 2024

Status Verified

May 1, 2024

Enrollment Period

5 days

First QC Date

May 7, 2024

Last Update Submit

May 15, 2024

Conditions

Keywords

Oral diseasesThyme honeyanti-inflammatorynatural products

Outcome Measures

Primary Outcomes (1)

  • Pain intensity

    Visual Analog Scale (0-10) will be used to determine the intensity of pain on day 0, day 3, day 5, and day 7.

    7 days.

Secondary Outcomes (2)

  • Size of ulcers (in mm)

    7 days.

  • The Oral Health Impact Profile (OHIP-14) questionnaire

    7 days

Study Arms (2)

Thyme honey

EXPERIMENTAL

10 patients will be treated by thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days.

Other: Thyme honey

kenalog in orabase

ACTIVE COMPARATOR

10 patients will be treated by kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g), three times a day for 7 days only.

Drug: Kenalog

Interventions

Thyme honey is a rich monofloral honey variety formed by bees that collect nectar from thymus vulgaris flowers. thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days

Thyme honey

kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g)

Also known as: kenalog in orabase
kenalog in orabase

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The study involved patients who had a positive history of having similar oral mucosal ulcers for 3-4 months and ulcers for \<48 h.
  • Clinically diagnosed patients with chronic aphthous stomatitis measuring ≤5 mm in size in the oral cavity and who gave written consent for participation.
  • Only single ulcers were considered for the study.
  • Systemically health patients.

You may not qualify if:

  • The study excluded patients with a history of associated systemic disease.
  • Cases of chronic aphthous stomatitis (major), lesions of herpetic form, numerous RAS lesions, and smoking.
  • In addition, no consideration was given to patients with a history of hypersensitivity to honey.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The British University in Egypt

Cairo, Egypt

Location

Related Publications (3)

  • Bang LM, Buntting C, Molan P. The effect of dilution on the rate of hydrogen peroxide production in honey and its implications for wound healing. J Altern Complement Med. 2003 Apr;9(2):267-73. doi: 10.1089/10755530360623383.

    PMID: 12804080BACKGROUND
  • Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis. 2005 Nov;11(6):338-49. doi: 10.1111/j.1601-0825.2005.01142.x.

    PMID: 16269024BACKGROUND
  • Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J. 1975 Oct 4;113(7):627-30.

    PMID: 1181018BACKGROUND

MeSH Terms

Conditions

Stomatitis, AphthousPatient Compliance

Interventions

Triamcinolone AcetonideTriamcinolone

Condition Hierarchy (Ancestors)

StomatitisMouth DiseasesStomatognathic DiseasesPatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

PregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Central Study Contacts

Dalia Ghalwash, Phd

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
the care provider and the outcomes assessor will not know which treatment will be given to the patients.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Thyme honey on recurrent aphthous stomatitis
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2024

First Posted

May 20, 2024

Study Start

May 10, 2024

Primary Completion

May 15, 2024

Study Completion

May 30, 2024

Last Updated

May 20, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Confidentiality of data: All data will be stored in an Excel sheet for research purposes and respecting patient confidentiality. Patients have the right to withdraw from the research at any point for any reason and with no penalty subject to them.

Locations